Former MinuteClinic exec shifts to Santa Rosa Community Health Centers
SANTA ROSA, Calif. Former MinuteClinic regional medical director Francisco Trilla has joined Santa Rosa Community Health Centers, according to local news reports.
Trilla will serve as the new chief medical officer of Santa Rosa Community Health Centers, overseeing clinical programs at all of its eight facilities with "an emphasis on access and quality," according to reports.
Trilla most recently worked at Beth Israel Deacones Medical Center. He also was chair of the licensing committee for the Massachusetts’ Board of Registration Medicine and was the medical director of Atreva Health Care. In addition, he served as regional medical director of MinuteClinic and an assistant clinical professor at Harvard Medical School.
NACDS, NCPA in joint statement praise CMS’ move to withdraw provisions of AMP rule currently blocked by injunction
ALEXANDRIA, Va. National Association of Chain Drug Stores president and CEO Steve Anderson and National Community Pharmacists Association acting EVP and CEO Douglas Hoey issued a statement praising the proposed rule by the Centers for Medicare and Medicaid Services that would withdraw existing provisions of the Medicaid pharmacy reimbursement formula under the average manufacturer price model.
"We are pleased that the Centers for Medicare and Medicaid Services has proposed a rule that would withdraw provisions of what is known as the Medicaid average manufacturer price rule. The proposed rule calls for the withdrawal of existing provisions that define AMP, that determine the calculation of federal upper limits, and that define ‘multiple source drug.’ Put simply, all of these provisions relate to the reimbursement to pharmacies for generic Medicaid prescriptions, and thus impact patients’ access to pharmacies. The move to withdraw these provisions is a victory for patient care as it is delivered in America’s pharmacies every day."
"When we filed the lawsuit in 2007 we knew that patient care was at stake. It is important to point out that the withdrawal of these provisions is another step toward reducing what would have been major cuts to pharmacy reimbursement. The end result is not an increase in reimbursement to pharmacy, but rather the lessening of cuts that previously would have involved pharmacies selling most generic drugs at a loss, thereby threatening their long-term ability to provide patient care."
“We insisted that this policy was not appropriate. Separately, we also have urged that policy-makers should recognize the ability of pharmacies and pharmacists to help improve health and reduce healthcare costs. We are gratified that this sense is reflected in the pharmacy provisions of the new healthcare-reform law. The new law contains provisions ranging from dramatically reducing the AMP cuts to advancing medication therapy management, through which pharmacists can help patients take their medications correctly. … The costs related to poor medication adherence have been estimated to reach $290 billion annually, or 13% of all healthcare expenditures. We urged that patient care should not be jeopardized, but rather that pharmacy be engaged more strategically for the good of patient health and healthcare delivery."
“We anticipate issuing formal comments on CMS’ proposed rule to withdraw these provisions of the AMP rule, and we will continue to work with Congress and with CMS to advocate for access to pharmacy services for patients.”
Teva markets AcuDial generic
NORTH WALES, Pa. Teva Pharmaceuticals has launched a generic treatment for epileptic seizures.
The world’s largest generic drug maker announced Wednesday the launch of diazepam rectal gel, a generic version of Valeant Pharmaceuticals’ Diastat AcuDial. The drug is administered via rectal syringe and is available in 2.5-mg, 10-mg and 20-mg strengths.
“Generic pharmaceuticals are playing an increasingly important role in healthcare cost containment,” Teva VP customer operations and marketing Maureen Cavanaugh said. “Teva Pharmaceuticals continues to lead the way with timely new product launches.”